Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07059832 | Application of 68Ga-NODAGA-SNA006 Positron Emission Tomography/Computed Tomography (PET/CT) in Tumors | PHASE1 | ACTIVE NOT_RECRUITING | 30 | — | — | Apr 1, 2024 | Apr 1, 2028 | Jul 11, 2025 | 1 | China |
Through PET/CT, Visual analysis was positive, or the SUVmax was more than the mediastinum
Through PET/CT analysis, SUVmax and SUVmean of the organs
| Arm | Type | Description |
|---|---|---|
| Feasibility and safety of 68Ga-NODAGA-SNA006 | EXPERIMENTAL | 68Ga-NODAGA-SNA006 0.05 mCi/Kg, interval time between FDG was within five days |
| Name | Type | Description |
|---|---|---|
| 68Ga-NODAGA-SNA006 | DRUG | 68Ga-NODAGA-SNA006 PET/CT: after intravenous injection of 0.05 mCi/kg body weight of quality-controlled 68Ga-NODAGA-SNA006, an integrated PET/CT scanner (Biograph mCT; Siemens, Germany) will be applied. |
Inclusion Criteria: 1. Participants who were diagnosed with malignant tumors; 2. Patients are between 18 and 80 years of age are between 18 and 80 years of age. Exclusion Criteria: 1. Participants who were unable or unwilling to provide written informed consent. 2. Participants who were unable to...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |